Business
£7.3m Influenza human challenge study contract win
£7.3m Influenza human challenge study contract win.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n Open Orphan plc\n \n \n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n \n \n \n \n \n £7.3m Influenza human challenge study contract win\n \n \n \n \n \n \n \n \n \n Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials\n , announces that\n \n hVIVO\n \n , a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (\"Study\") contract with a leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model.\n \n \n \n \n \n The randomised, double-blinded, placebo-controlled study\n will test and assess the antiviral prophylactic and post-inoculation treatment activity of the antiviral in healthy adult volunteers enrolled through the Company's specialist, tech-enabled volunteer recruitment arm,\n \n FluCamp\n \n . The Study will be\n conducted by hVIVO's team of medics at its state-of-the-art quarantine facilities in London and\n \n is expected to commence next year. R\n evenue from the contract is expected to be recognised across FY23 and FY24.\n \n \n \n \n \n T\n \n he Company's specialised virology laboratories, \n h\n LAB, will determine\n \n \n the viral load of the influenza challenge agent used to inoculate volunteers,\n \n h\n \n LAB\n will also provide\n serology services and virology services\n \n (viral infectivity assay) for the study.\n \n \n \n \n \n Influenza is a contagious respiratory illness caused by influenza viruses that affect the nose, throat and the lungs. It can cause mild to severe illness, and occasionally lead to death. According to Financial Times1 analysis of official data in England, since the development of effective vaccines and the emergence of the less severe Omicron variant, influenza is now more lethal than COVID-19. For every 100,000 Omicron infections, 35 will result in death, while the equivalent number of flu infections will lead to around 40 fatalities.\n \n \n \n \n \n \n Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said\n :\n \n \"I am pleased to sign a contract with this leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model. hVIVO...